Biogen's tau-targeting drug diranersen produced a striking split result: it clearly lowered tau in the brain and hinted at slower decline, yet it missed its main statistical goal. Researchers are excited because it is the first randomized trial to link lowering tau to a possible cognitive benefit, and cautious because that benefit was not statistically significant and came from small patient groups.
Diranersen (formerly BIIB080) is an investigational antisense oligonucleotide — a lab-made strand of genetic material designed to shut down tau production at its source. It is not FDA-approved. The excitement and the caution both come from the Phase 2 CELIA study, whose full data Biogen presented in July 2026.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What diranersen is and why tau matters
- What the CELIA study actually found
- Why researchers are still excited
- Why caution is warranted
- What this means for patients and families
- Frequently Asked Questions
What diranersen is and why tau matters
alzheimer's disease involves two abnormal proteins: amyloid, which forms plaques between brain cells, and tau, which forms tangles inside them. Most approved drugs target amyloid. Diranersen instead targets tau, aiming to reduce both the tau inside cells and the tau released outside them. According to Biogen's announcement, diranersen is a first-in-class antisense oligonucleotide that lowers tau production at its source.
This is a different strategy from clearing plaques, and it is why the trial drew close attention regardless of the outcome. The drug is given by intrathecal delivery, meaning a lumbar puncture that places medicine into the spinal fluid. It is not a simple injection or an IV infusion. That delivery route shapes both who might use it and what side effects to expect.
What the CELIA study actually found
CELIA (NCT05399888) was an 18-month randomized, placebo-controlled trial in people with early Alzheimer's, testing three dosing regimens. The study measured decline using CDR-SB, a standard scale that rates memory, judgment, and daily function; higher scores mean more impairment. The trial did not meet its primary endpoint.
As NeurologyLive reported, CELIA was designed to show a dose-response — bigger doses producing bigger benefits — but the lowest dose performed best, which defeated that goal. The most encouraging number came from the 60 mg dose given every 24 weeks. The Alzheimer's Association summary notes this dose slowed decline by 0.54 points, or 26%, on CDR-SB versus placebo. The catch: that difference was not statistically significant, so it could reflect chance.
Why researchers are still excited
The strongest signal was biological, not just clinical. Biogen reported robust, reproducible tau reductions in spinal fluid and brain across all doses, in both Phase 1 and Phase 2. The company frames this as the first randomized evidence linking tau lowering to a cognitive benefit. That link is the scientific prize.
For years, researchers have debated whether reducing tau would actually help people think and function, or merely change a lab measurement. A consistent drop in tau alongside a hint of slower decline is the kind of paired result that justifies a larger trial. Regulators have signaled interest too. The FDA granted BIIB080 Fast Track designation in April 2025, an expedited-review pathway. Fast Track speeds up the review process; it is not an approval and does not mean the drug works.
Why caution is warranted
The headline caveat is simple: the study missed its primary endpoint, and its best result was not statistically significant. A 26% slowing sounds meaningful, but without statistical significance, scientists cannot rule out that it happened by chance. The independent view reinforces this. The Alzheimer's Association called the tau-and-cognition findings encouraging but preliminary, pointing to the endpoint miss and the small size of each dose group.
Small groups make promising numbers less reliable. Safety adds another layer to weigh. Diranersen was generally well tolerated, but the common events reflect its delivery method: None of this makes the drug available today. It remains investigational, and access outside a trial is not possible.
- Procedural pain from the lumbar puncture
- Post-lumbar-puncture syndrome (headache and related symptoms)
- Mostly transient confusional states
- More serious adverse events at the highest dose
What this means for patients and families
Despite the endpoint miss, Biogen plans to advance diranersen to registrational, or Phase 3, development based on the biomarker and efficacy signals. That means more testing lies ahead before any approval decision, likely years away. For readers, the practical takeaways are modest but real: You can track the trial's official record through the CELIA Phase 2 registry at ClinicalTrials.gov, which lists study status, sites, and eligibility criteria.
- Diranersen is not a treatment you can request now; it is still in trials.
- Any future use would involve a spinal procedure, not a pill or standard infusion.
- Tau-targeting is a genuinely new direction, separate from today's amyloid drugs.
- Watch for Phase 3 enrollment if you or a loved one has early Alzheimer's.
Frequently Asked Questions
Is diranersen approved or available now?
No. It is investigational and not FDA-approved. It received Fast Track designation in 2025, which speeds review but is not an approval, and access is limited to clinical trials.
Did the drug fail?
Not exactly. CELIA missed its primary endpoint and its best result was not statistically significant, but it lowered tau consistently and hinted at slower decline — enough for Biogen to plan Phase 3.
How is diranersen given?
Through intrathecal delivery, a lumbar puncture that places the medicine into spinal fluid, dosed every 12 or 24 weeks depending on the regimen. It is not an injection or IV infusion.
